Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
The burden of injuries in Iranian children in 2005.

Population health metrics

Naghavi M, Pourmalek F, Shahraz S, Jafari N, Delavar B, Motlagh ME.
PMID: 20356350
Popul Health Metr. 2010 Mar 31;8:5. doi: 10.1186/1478-7954-8-5.

BACKGROUND: Child injury is recognized as a global health problem. Injuries caused the highest burden of disease among the total population of Iran in 2003. We aimed to estimate the morbidity, mortality, and disease burden caused by child injuries...

Cite
Naghavi M, Pourmalek F, Shahraz S, et al. The burden of injuries in Iranian children in 2005. Popul Health Metr. 2010;8:5doi: 10.1186/1478-7954-8-5.
Naghavi, M., Pourmalek, F., Shahraz, S., Jafari, N., Delavar, B., & Motlagh, M. E. (2010). The burden of injuries in Iranian children in 2005. Population health metrics, 85. https://doi.org/10.1186/1478-7954-8-5
Naghavi, Mohsen, et al. "The burden of injuries in Iranian children in 2005." Population health metrics vol. 8 (2010): 5. doi: https://doi.org/10.1186/1478-7954-8-5
Naghavi M, Pourmalek F, Shahraz S, Jafari N, Delavar B, Motlagh ME. The burden of injuries in Iranian children in 2005. Popul Health Metr. 2010 Mar 31;8:5. doi: 10.1186/1478-7954-8-5. PMID: 20356350; PMCID: PMC2853502.
Copy Download .nbib Format: NLM
Iranian pharmacists' knowledge, attitude and practice regarding counterfeit drugs.

Iranian journal of pharmaceutical research : IJPR

Shahverdi S, Hajimiri M, Pourmalek F, Torkamandi H, Gholami K, Hanafi S, Ashrafi Shahmirzadi N, Javadi M.
PMID: 24250525
Iran J Pharm Res. 2012;11(3):963-8.

Background Awareness of pharmacists about counterfeit drugs is necessary for health improvement in community. The purpose of the present study is to assess the knowledge and measure the professional attitude and practice of Iranian pharmacist about counterfeit drugs. In...

Cite
Shahverdi S, Hajimiri M, Pourmalek F, et al. Iranian pharmacists' knowledge, attitude and practice regarding counterfeit drugs. Iran J Pharm Res. 2012;11(3):963-8
Shahverdi, S., Hajimiri, M., Pourmalek, F., Torkamandi, H., Gholami, K., Hanafi, S., Ashrafi Shahmirzadi, N., & Javadi, M. (2012). Iranian pharmacists' knowledge, attitude and practice regarding counterfeit drugs. Iranian journal of pharmaceutical research : IJPR, 11(3), 963-8.
Shahverdi, Shieda, et al. "Iranian pharmacists' knowledge, attitude and practice regarding counterfeit drugs." Iranian journal of pharmaceutical research : IJPR vol. 11,3 (2012): 963-8.
Shahverdi S, Hajimiri M, Pourmalek F, Torkamandi H, Gholami K, Hanafi S, Ashrafi Shahmirzadi N, Javadi M. Iranian pharmacists' knowledge, attitude and practice regarding counterfeit drugs. Iran J Pharm Res. 2012;11(3):963-8. PMID: 24250525; PMCID: PMC3813117.
Copy Download .nbib Format: NLM
Tumor MHC Class I Expression Associates with Intralesional Interleukin-2 Response in Melanoma.

Cancer immunology research

Pourmaleki M, Jones CJ, Ariyan CE, Zeng Z, Pirun M, Navarrete DA, Li Y, Zhang M, Nandakumar S, Campos C, Nadeem S, Klimstra DS, Temple-Oberle CF, Brenn T, Lipson EJ, Schenk KM, Stein JE, Taube JM, White MG, Traweek R, Wargo JA, Kirkwood JM, Gasmi B, Goff SL, Corwin AD, McDonough E, Ginty F, Callahan MK, Schietinger A, Socci ND, Mellinghoff IK, Hollmann TJ.
PMID: 35013003
Cancer Immunol Res. 2022 Jan 10; doi: 10.1158/2326-6066.CIR-21-1083. Epub 2022 Jan 10.

Cancer immunotherapy can result in lasting tumor regression, but predictive biomarkers of treatment response remain ill-defined. Here, we performed single-cell proteomics, transcriptomics, and genomics on matched untreated and interleukin-2 (IL-2) injected metastases from patients with melanoma. Lesions that completely...

Cite
Pourmaleki M, Jones CJ, Ariyan CE, et al. Tumor MHC Class I Expression Associates with Intralesional Interleukin-2 Response in Melanoma. Cancer Immunol Res. 2022;doi: 10.1158/2326-6066.CIR-21-1083.
Pourmaleki, M., Jones, C. J., Ariyan, C. E., Zeng, Z., Pirun, M., Navarrete, D. A., Li, Y., Zhang, M., Nandakumar, S., Campos, C., Nadeem, S., Klimstra, D. S., Temple-Oberle, C. F., Brenn, T., Lipson, E. J., Schenk, K. M., Stein, J. E., Taube, J. M., White, M. G., Traweek, R., Wargo, J. A., Kirkwood, J. M., Gasmi, B., Goff, S. L., Corwin, A. D., McDonough, E., Ginty, F., Callahan, M. K., Schietinger, A., Socci, N. D., Mellinghoff, I. K., & Hollmann, T. J. (2022). Tumor MHC Class I Expression Associates with Intralesional Interleukin-2 Response in Melanoma. Cancer immunology research, . https://doi.org/10.1158/2326-6066.CIR-21-1083
Pourmaleki, Maryam, et al. "Tumor MHC Class I Expression Associates with Intralesional Interleukin-2 Response in Melanoma." Cancer immunology research vol. (2022). doi: https://doi.org/10.1158/2326-6066.CIR-21-1083
Pourmaleki M, Jones CJ, Ariyan CE, Zeng Z, Pirun M, Navarrete DA, Li Y, Zhang M, Nandakumar S, Campos C, Nadeem S, Klimstra DS, Temple-Oberle CF, Brenn T, Lipson EJ, Schenk KM, Stein JE, Taube JM, White MG, Traweek R, Wargo JA, Kirkwood JM, Gasmi B, Goff SL, Corwin AD, McDonough E, Ginty F, Callahan MK, Schietinger A, Socci ND, Mellinghoff IK, Hollmann TJ. Tumor MHC Class I Expression Associates with Intralesional Interleukin-2 Response in Melanoma. Cancer Immunol Res. 2022 Jan 10; doi: 10.1158/2326-6066.CIR-21-1083. Epub 2022 Jan 10. PMID: 35013003.
Copy Download .nbib Format: NLM
Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A.

Oncotarget

Pourmaleki M, Young JH, Socci ND, Chiang S, Edelweiss M, Li Y, Zhang M, Roshal L, Chi DS, Busam KJ, Mellinghoff IK, Hollmann TJ.
PMID: 31692889
Oncotarget. 2019 Oct 22;10(58):6152-6167. doi: 10.18632/oncotarget.27247. eCollection 2019 Oct 22.

Extramammary Paget disease (EMPD) is a rare cutaneous adenocarcinoma of the anogenital region most commonly treated with surgical excision. Surgical margin clearance is often problematic and recurrence rates remain high indicating the need for additional therapeutic options. Topical immunomodulators...

Cite
Pourmaleki M, Young JH, Socci ND, et al. Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A. Oncotarget. 2019;10(58):6152-6167doi: 10.18632/oncotarget.27247.
Pourmaleki, M., Young, J. H., Socci, N. D., Chiang, S., Edelweiss, M., Li, Y., Zhang, M., Roshal, L., Chi, D. S., Busam, K. J., Mellinghoff, I. K., & Hollmann, T. J. (2019). Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A. Oncotarget, 10(58), 6152-6167. https://doi.org/10.18632/oncotarget.27247
Pourmaleki, Maryam, et al. "Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A." Oncotarget vol. 10,58 (2019): 6152-6167. doi: https://doi.org/10.18632/oncotarget.27247
Pourmaleki M, Young JH, Socci ND, Chiang S, Edelweiss M, Li Y, Zhang M, Roshal L, Chi DS, Busam KJ, Mellinghoff IK, Hollmann TJ. Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A. Oncotarget. 2019 Oct 22;10(58):6152-6167. doi: 10.18632/oncotarget.27247. eCollection 2019 Oct 22. PMID: 31692889; PMCID: PMC6817453.
Copy Download .nbib Format: NLM
Algorithms for enhancing public health utility of national causes-of-death data.

Population health metrics

Naghavi M, Makela S, Foreman K, O'Brien J, Pourmalek F, Lozano R.
PMID: 20459720
Popul Health Metr. 2010 May 10;8:9. doi: 10.1186/1478-7954-8-9.

BACKGROUND: Coverage and quality of cause-of-death (CoD) data varies across countries and time. Valid, reliable, and comparable assessments of trends in causes of death from even the best systems are limited by three problems: a) changes in the International...

Cite
Naghavi M, Makela S, Foreman K, et al. Algorithms for enhancing public health utility of national causes-of-death data. Popul Health Metr. 2010;8:9doi: 10.1186/1478-7954-8-9.
Naghavi, M., Makela, S., Foreman, K., O'Brien, J., Pourmalek, F., & Lozano, R. (2010). Algorithms for enhancing public health utility of national causes-of-death data. Population health metrics, 89. https://doi.org/10.1186/1478-7954-8-9
Naghavi, Mohsen, et al. "Algorithms for enhancing public health utility of national causes-of-death data." Population health metrics vol. 8 (2010): 9. doi: https://doi.org/10.1186/1478-7954-8-9
Naghavi M, Makela S, Foreman K, O'Brien J, Pourmalek F, Lozano R. Algorithms for enhancing public health utility of national causes-of-death data. Popul Health Metr. 2010 May 10;8:9. doi: 10.1186/1478-7954-8-9. PMID: 20459720; PMCID: PMC2873308.
Copy Download .nbib Format: NLM
The burden of disease and injury in Iran 2003.

Population health metrics

Naghavi M, Abolhassani F, Pourmalek F, Lakeh M, Jafari N, Vaseghi S, Mahdavi Hezaveh N, Kazemeini H.
PMID: 19527516
Popul Health Metr. 2009 Jun 15;7:9. doi: 10.1186/1478-7954-7-9.

BACKGROUND: The objective of this study was to estimate the burden of disease and injury in Iran for the year 2003, using Disability-Adjusted Life Years (DALYs) at the national level and for six selected provinces.METHODS: Methods developed by the...

Cite
Naghavi M, Abolhassani F, Pourmalek F, et al. The burden of disease and injury in Iran 2003. Popul Health Metr. 2009;7:9doi: 10.1186/1478-7954-7-9.
Naghavi, M., Abolhassani, F., Pourmalek, F., Lakeh, M., Jafari, N., Vaseghi, S., Mahdavi Hezaveh, N., & Kazemeini, H. (2009). The burden of disease and injury in Iran 2003. Population health metrics, 79. https://doi.org/10.1186/1478-7954-7-9
Naghavi, Mohsen, et al. "The burden of disease and injury in Iran 2003." Population health metrics vol. 7 (2009): 9. doi: https://doi.org/10.1186/1478-7954-7-9
Naghavi M, Abolhassani F, Pourmalek F, Lakeh M, Jafari N, Vaseghi S, Mahdavi Hezaveh N, Kazemeini H. The burden of disease and injury in Iran 2003. Popul Health Metr. 2009 Jun 15;7:9. doi: 10.1186/1478-7954-7-9. PMID: 19527516; PMCID: PMC2711041.
Copy Download .nbib Format: NLM
Deadly rural road traffic injury: a rising public health concern in I.R. Iran.

International journal of preventive medicine

Ardalan A, Sepehrvand N, Pourmalek F, Masoumi G, Sarvar M, Mahmoudabadi A, Rezaie A.
PMID: 24627755
Int J Prev Med. 2014 Feb;5(2):241-4.

BACKGROUND: The 5(th) Iran National Development Plan, 2011-2015, has emphasized on expansion of rural asphalt roads. This article aims to illustrate the trend of deaths caused by rural road traffic crashes (RTCs) and its association with length of the...

Cite
Ardalan A, Sepehrvand N, Pourmalek F, et al. Deadly rural road traffic injury: a rising public health concern in I.R. Iran. Int J Prev Med. 2014;5(2):241-4
Ardalan, A., Sepehrvand, N., Pourmalek, F., Masoumi, G., Sarvar, M., Mahmoudabadi, A., & Rezaie, A. (2014). Deadly rural road traffic injury: a rising public health concern in I.R. Iran. International journal of preventive medicine, 5(2), 241-4.
Ardalan, Ali, et al. "Deadly rural road traffic injury: a rising public health concern in I.R. Iran." International journal of preventive medicine vol. 5,2 (2014): 241-4.
Ardalan A, Sepehrvand N, Pourmalek F, Masoumi G, Sarvar M, Mahmoudabadi A, Rezaie A. Deadly rural road traffic injury: a rising public health concern in I.R. Iran. Int J Prev Med. 2014 Feb;5(2):241-4. PMID: 24627755; PMCID: PMC3950751.
Copy Download .nbib Format: NLM
COVID-19 in Iran: What was done and what should be done.

Medical journal of the Islamic Republic of Iran

Nojomi M, Moradi-Lakeh M, Pourmalek F.
PMID: 34956943
Med J Islam Repub Iran. 2021 Jul 29;35:97. doi: 10.47176/mjiri.35.97. eCollection 2021.

The current COVID-19 pandemic started in Wuhan, China, in December 2019. The World health Organization (WHO) declared the COVID-19 as a public health emergency of international concern on January 30, 2020, and recognized the situation as a pandemic on...

Cite
Nojomi M, Moradi-Lakeh M, Pourmalek F. COVID-19 in Iran: What was done and what should be done. Med J Islam Repub Iran. 2021;35:97doi: 10.47176/mjiri.35.97.
Nojomi, M., Moradi-Lakeh, M., & Pourmalek, F. (2021). COVID-19 in Iran: What was done and what should be done. Medical journal of the Islamic Republic of Iran, 3597. https://doi.org/10.47176/mjiri.35.97
Nojomi, Marzieh, et al. "COVID-19 in Iran: What was done and what should be done." Medical journal of the Islamic Republic of Iran vol. 35 (2021): 97. doi: https://doi.org/10.47176/mjiri.35.97
Nojomi M, Moradi-Lakeh M, Pourmalek F. COVID-19 in Iran: What was done and what should be done. Med J Islam Repub Iran. 2021 Jul 29;35:97. doi: 10.47176/mjiri.35.97. eCollection 2021. PMID: 34956943; PMCID: PMC8683782.
Copy Download .nbib Format: NLM
Assessing health system responsiveness: a household survey in 17th district of tehran.

Iranian Red Crescent medical journal

Rashidian A, Kavosi Z, Majdzadeh R, Pourreza A, Pourmalek F, Arab M, Mohammad K.
PMID: 22737485
Iran Red Crescent Med J. 2011 May;13(5):302-8. Epub 2011 May 01.

BACKGROUND: Responsiveness is an indicator by WHO to evaluate the performance of health systems on nonmedical expectations of consumers. This study measures the health system responsiveness and the factors affecting responsiveness in Iran health system.METHODS: World Health Survey (WHS)...

Cite
Rashidian A, Kavosi Z, Majdzadeh R, et al. Assessing health system responsiveness: a household survey in 17th district of tehran. Iran Red Crescent Med J. 2011;13(5):302-8
Rashidian, A., Kavosi, Z., Majdzadeh, R., Pourreza, A., Pourmalek, F., Arab, M., & Mohammad, K. (2011). Assessing health system responsiveness: a household survey in 17th district of tehran. Iranian Red Crescent medical journal, 13(5), 302-8.
Rashidian, A, et al. "Assessing health system responsiveness: a household survey in 17th district of tehran." Iranian Red Crescent medical journal vol. 13,5 (2011): 302-8.
Rashidian A, Kavosi Z, Majdzadeh R, Pourreza A, Pourmalek F, Arab M, Mohammad K. Assessing health system responsiveness: a household survey in 17th district of tehran. Iran Red Crescent Med J. 2011 May;13(5):302-8. Epub 2011 May 01. PMID: 22737485; PMCID: PMC3371967.
Copy Download .nbib Format: NLM
COVID-19 in Iran: What was done and what should be done.

Medical journal of the Islamic Republic of Iran

Nojomi M, Moradi-Lakeh M, Pourmalek F.
PMID: 34956943
Med J Islam Repub Iran. 2021 Jul 29;35:97. doi: 10.47176/mjiri.35.97. eCollection 2021.

The current COVID-19 pandemic started in Wuhan, China, in December 2019. The World health Organization (WHO) declared the COVID-19 as a public health emergency of international concern on January 30, 2020, and recognized the situation as a pandemic on...

Cite
Nojomi M, Moradi-Lakeh M, Pourmalek F. COVID-19 in Iran: What was done and what should be done. Med J Islam Repub Iran. 2021;35:97doi: 10.47176/mjiri.35.97.
Nojomi, M., Moradi-Lakeh, M., & Pourmalek, F. (2021). COVID-19 in Iran: What was done and what should be done. Medical journal of the Islamic Republic of Iran, 3597. https://doi.org/10.47176/mjiri.35.97
Nojomi, Marzieh, et al. "COVID-19 in Iran: What was done and what should be done." Medical journal of the Islamic Republic of Iran vol. 35 (2021): 97. doi: https://doi.org/10.47176/mjiri.35.97
Nojomi M, Moradi-Lakeh M, Pourmalek F. COVID-19 in Iran: What was done and what should be done. Med J Islam Repub Iran. 2021 Jul 29;35:97. doi: 10.47176/mjiri.35.97. eCollection 2021. PMID: 34956943; PMCID: PMC8683782.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries